Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
September 24, 2024 06:00 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
LiveOne (NASDAQ: LVO) Brands Expands into California and Georgia’s $47 Billion Wine Markets
September 24, 2024 06:00 ET
|
Liveone, Inc.
- Expands distribution of “Birthday Sex” wine in collaboration with R&B star Jeremih - Enters into distribution partnerships with SOKO and Kelly Family Distributors LOS ANGELES, Sept. 24,...
LGI Homes Recognized as one of the World’s Most Trustworthy Companies for the Second Consecutive Year by Newsweek
September 24, 2024 06:00 ET
|
LGI Homes, Inc.
LGI Homes has been named on Newsweek’s list of the World’s Most Trustworthy Companies 2024.
Double the Goodness: El Pollo Loco Celebrates National Quesadilla Day with an Exclusive BOGO Offer
September 24, 2024 06:00 ET
|
El Pollo Loco Holdings, Inc.
El Pollo Loco celebrates National Quesadilla Day on 9/25 and 9/26 with a BOGO offer for Loco Rewards members on Chicken Avocado Stuffed Quesadillas.
Lotus Deploys Ambarella’s Oculii™ AI 4D Imaging Radar Technology in L2+ Semi-Autonomous Systems for Eletre SUV and Emeya Hyper-GT Electric Vehicles
September 24, 2024 05:00 ET
|
Ambarella
Ambarella announced that its Oculii™ AI 4D imaging radar technology is deployed worldwide in the Lotus Eletre SUV and Emeya Hyper-GT Electric Vehicles.
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
September 24, 2024 03:00 ET
|
HUTCHMED (China) Limited
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the...
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
September 24, 2024 01:00 ET
|
Biogen Inc.
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...
Duolingo Introduces AI-Powered Innovations at Duocon 2024
September 24, 2024 00:01 ET
|
Duolingo, Inc.
PITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Duolingo (NASDAQ:DUOL), the world’s leading mobile learning platform, today announces significant product innovations at its annual conference, Duocon...
BioVie Inc. Announces Pricing of Public Offering
September 23, 2024 22:26 ET
|
BioVie, Inc.
CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic...
Nova Minerals Limited Announces Pricing of Public Offering
September 23, 2024 20:00 ET
|
NOVA MINERALS LIMITED
Caufield, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Nova Minerals Limited (“Nova” and the “Company”) (Nasdaq NVA, NVAWW) (ASX: NVA), (OTC: NVAAF)(FSE: QM3)), a gold and critical minerals...